Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
2010 · Journal of Clinical Oncology · 523 citations
https://doi.org/10.1200/jco.2009.25.8707
Y
Yan Sun
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
196
Papers
10.5K
Citations
39
h-index
86
i10-index
Yan Sun is an academic researcher from Peking University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Head and Neck Cancer Studies & Lung Cancer Research Studies. The author has an h-index of 39, co-authored 167 publications.
ORCID: 0000-0001-8525-7814Papers by this author
worksConcurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long‐term results of phase 3 randomized controlled trial
2019 · International Journal of Cancer · 244 citations
https://doi.org/10.1002/ijc.32099
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
2010 · Investigational New Drugs · 193 citations
https://doi.org/10.1007/s10637-010-9438-y
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer
2021 · Annals of Oncology · 84 citations
https://doi.org/10.1016/j.annonc.2021.08.1752
Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer
2021 · Cell Death and Disease · 54 citations
https://doi.org/10.1038/s41419-021-04118-4
Comparison of CBV, BEAM and BEAC high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non‐Hodgkin lymphoma: Efficacy and toxicity
2017 · Asia-Pacific Journal of Clinical Oncology · 25 citations
https://doi.org/10.1111/ajco.12610
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat